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PLANNING, CONDUCT AND EVALUATION OF CONTROLLED CLINICAL
TRIALS*
S. RADHAKRISHNA
(From Tuberculosis Chemotherapy Centre, Madras)
The controlled clinical trial is now a well-
accepted method of measuring the relative effi-
very clearly the type of patients to be admitted.
cacies of different therapeutic regimens for
To give an example, Slide 2 sets out the impor-
many diseases.
tant criteria employed at the Tuberculosis
Although its usefulness is   Chemotherapy Centre, Madras.
widely appreciated, there is an insufficient
awareness of the rationale and the methodology
of the controlled clinical trial– that is, the rea-
sons underlying it and the procedures involved
in the execution. By taking examples from the
field of pulmonary tuberculosis, the issues in-
volved can be clearly set out.
2. Choice of Patients for study at the T,C.C., Madras
Specification of regimen and priority in aims Bacteriologically confirmed pul. Tb.
To evaluate the efficacy, toxicity and accep-
tability of an anti-tuberculosis regimen – for
instance, isoniazid plus thioacetazone, it is
necessary to start with very clear ideas of the
dosage, the rhythm of administration and the
exact duration of the regimen. Next comes
specification of the order of priority in aims as
there can be a clash of interests. For instance,
4. Drug-sensitive organisms
5. Bonafide residents
I. Specification of Regimen and Priority in Aims
It is important also to specify contra-indica-
tions for admission to the study – for example,
patients with leprosy or diabetes, since their
management would be rather complicated.
The next requirement is a control group of
patients.
Specify clearly
(a) dosage, rhythm and duration
(b) priority in aims
(1) Efficacy
(2) Toxicity
(3) Acceptability
if the main aim is to determine the efficacy of
the drugs: it will obviously be necessary to
employ procedures for detecting irregularities
in drug-collection and drug-intake, and correct-
ing them. Such action would, however, mean
that pressure is applied on patients when they
show evidence of non-acceptability, thereby
making any assessment of the acceptability of
the regimen rather artificial. This is a good
Need for control
Slide 3 gives some interesting examples  
of entirely inaccurate or highly misleading con-
clusions that one might draw in the absence of
a control group of patients.
3. Need for Control
Giddiness
Strep. + INAH 35% of 78
PAS + INAH 11% of 70
illustration of the basic maxim that any study
can have only one main aim. The first example refers to relapse rates inpatients with bacteriologically quiescent tuber-
Choice of patients for study at the T.C.C., culosis. In patients who received chemotherapy
Madras for 3 years, the total relapse rate in the third,
fourth-and fifth years was only 1%. This low
For any generalisation to be possible from proportion could have led to the recommenda-
the results of a study, it is necessary to define tion that 3 years of chemotherapy is absolutely
* This paper was presented as a lecture at the 24th
necessary to keep the relapse rate low. (Indeed,
National Conference on TB and Chest Diseases, held
similar recommendations have been made in
in Trivandrum in Jan. 1969 the literature, in the absence of controls). Such
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a recommendation is, however, totally unwarn-
ted since, in the patients who received only 2
years of chemotherapy, the relapse rate was
0%.
standards for smears, cultures, sensitivity tests
and urine tests. Obviously, the only way out of
these dangers is to have a control group that
is concurrent.
The next example is a less extreme one, and
pertains to toxicity. In a group of patients
treated with a twice-weekly regimen of strep-
tomycin plus isoniazid, 35% complained of
giddiness on at least one occasion during the
year of chemotherapy. However, 11 % of the
control group (who received a standard regi-
men of PAS plus isoniazid) also complained of
giddiness. Thus, in the absence of the control
group, we would have acquired an exaggerated
picture of streptomycin toxicity.
Number of patients to he admitted
Examples like this are plentiful. For ins-
tance, in the treatment of tuberculosis, conclu-
sions about the value of gold therapy, value of
hospitalization and role of diet have been
drawn and, in the case of the latter two, are
still being drawn without having a control
group of patients.
Next, let us consider the question which is
most frequently posed to the statistician, namely,
“How many patients must I admit to the study
to obtain a statistically valid result ?” Unfor-
tunately, the short answer to this question is
that there is no such magic number. However,
if the clinician can indicate to the statistician
the approximate efficacy of the control regimen
and, furthermore, state what difference from
the control regimen he would regard as having
practical importance, the statistician can then
tell them approximately how many patients
should be admitted.
These examples will have convinced you of
the necessity for having a control group of
patients, In the present context, the control
  might be a regimen that is already in use at
your clinic, for instance, a standard regimen of
isoniazid plus PAS.
To take an example, the clinician might be
interested in the new regimen only if it is 20%
more effective than the control regimen, which
from previous experience is known to have an
efficacy of 75%. In this case–that is, an effi-
cacy of 75% for the control and 95% for the
new regimen, approximately 70 patients will
have to be admitted to the study (that is, 35 in
each series) to demonstrate statistical signifi-
cance. If, however, the clinician wishes to
4. Need for Concurrency 5. Number of Patients to be Admitted
Factors that could vary
1. Disease condition of patients
Control
regimen
New
regimen
No. of patients
to be admitted
2. Co-operation of patients
75% 95% 70
3. Clinic supervision
75% 90% 130
   4. Laboratory standards
75% 85% 290
75% 80% 1150
Next, it is essential that the control should   
be a concurrent one. Comparisons with a non-
concurrent control–that is, retrospective com- detect a smaller degree of superiority, say 15%
parisons–are usually dangerous, as there are (that is, an efficacy of 90% for the new regi-
many factors that could vary from one point in men), the number required will be 130. The
time to another. For instance; the disease con- corresponding number for a 10% superiority
dition of the patients admitted to treatment will be 290, and for a 5% superiority 1150.
might be different in different years, on account Thus. the smaller the difference to be detected,
 of changes in diagnostic measures or influence the larger will be the number of patients
of mass propaganda campaigns. The co-opera- required. It must be noted that the
tion displayed by the patients might also vary number required for statistical significance will
from one year to another, possibly due to socio- depend not only on the size of the difference
economic causes. Thirdly, the intensity of to be detected, but also on the absolute levels
examination and the overall quality of the cli- of efficacy of the two regimens.
nic supervision might be different, especially if
there have been changes in the personnel. A It is worth stressing at this stage that statis-
similar problem can arise with the laboratory tical significance need not be the sole criterion
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for determining the number of patients to be
admitted. Very often, we are just as interested
in obtaining as precise an estimate as possible
of the efficacy of the new regimen. Obviously,
the larger the number of patients admitted, the
more precise will be the estimate. For instance,
if the efficacy was found to be 80% in a sample
of 100 patients, it may be stated, with 95%
confidence, that the true efficacy lies within
80±8%. If, however, the efficacy of 80% had
been observed in a larger sample of patients,
say 400, the limits will naturally be narrower,
namely, 80±4%.
Summing up, the decision regarding the
number to be admitted must be based on objec-
tive considerations like statistical significance
and high precision. Practical considerations
like availability of patients, drugs and facilities
are no doubt important but should always be
regarded as secondary.
Mode of deciding the regimen for individual
patients
Next comes the mode of deciding the treat-
ment regimen for individual patients. In a
controlled clinical trial, the mode of deciding
the regimen for any individual patient must
not only be free of bias, but also appear to be
free of bias. One can readily see the danger in
entrusting the choice of the regimen for indi-
vidual patients to the clinician. To take a simple
6. Mode of deciding the Regimen for individual
Patients
1. Clinician’s choice
2. Alternation
3. Random allocation from sealed envelopes
example, if patients were to be treated at home
or in sanatorium at the clinician’s discretion
(which might be, in some instances, influenced
by the patient’s wishes), it is almost certain that
the iller patients would tend to be admitted to
sanatorium while the less ill patients would be
treated at home.
Another highly undesirable procedure is the
method of alternation, whereby the first patient
is prescribed regimen A, the second regimen B,
the third regimen A, the fourth regimen B, and
so on. A variant of this is to admit all pati-
ents on odd days to the regimen A and those
on even days to the regimen B. Such proce-
dures are, however, capable of bias because the
order in which patients are admitted to a study
can be manipulated without much difficulty.
For instance, in a study of anticoagulant the-
rapy in myocardial infarction (quoted by
Truelove), the system of alternation resulted
in 580 treated patients and only 442 control
patients, a difference that could have occurred
by chance in only 1 of 5,000 occasions.
The best protection against all accusations
of bias is random allocation from sealed
envelopes. This procedure may be regarded as
the equivalent of tossing a coin. In practice, it
consists of preparing a treatment regimen list
for successive patients based on random num-
bers that are available in statistical tables and
incorporating it into sealed envelopes. Each
sealed envelope must have written on its exte-
rior the name of the study, and a sequential
serial number. Inside each envelope, there
should be a slip of paper giving the name of
the study, the sequential serial number and the
regimen for the patient. When a patient is
found suitable for admission to the study, his
treatment regimen is to be determined by
tearing open the next in the series of sealed
envelopes.
Purpose of random allocation
The purpose of random allocation is to
avoid personal preferences in the choice of
treatment for individual patients. It has to be
emphasised that these personal preferences can
be conscious or, more often, sub-conscious.
7. Purpose of random allocation
1. To avoid personal preferences,
conscious or sub-conscious
2. To construct two groups similar in all aspects
(a) known and measurable (stratification)
(b) known but immeasurable
(c) unknown
Failure to recognise that there is such a thing
as sub-conscious bias has often led investigators
to regard random allocation as a slur on their
personal honesty.
The great advantage of random allocation
is that it is highly likely to result in the cons-
truction of 2 groups which are similar in all
aspects–known and measurable, known but im-
measurable or not measured, as well as the un-
known. In the case of known and measurable
characteristics that have prognostic importance,
a further precaution would be to stratify the
patients into 2 or more groups – e.g. non-cavita-
ted and cavitated – and undertake the allocation
 from separate series of sealed envelopes, one for
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each group. In the present example, this
procedure will ensure that the two series have
identical proportions of cavitated patients.
Similarity in subsequent management
Next, it is important to ensure similarity in
the subsequent management of the patients in
the 2 series. For this, it is necessary to set out
in advance (1) the intensity of examination
during treatment-clinical, x-ray, sputum etc.,
(2) the nature and frequency of checks on drug-
8. Similarity in subsequent management
detail – that is to say, no deviations can be
made to suit the needs of individual patients or
individual clinicians.
To facilitate strict adherance to the protocol,
it is useful to have the important aspects (e.g.
criteria for eligibility to study, intensity of the
x-ray and sputum examinations, weight-dosage
schedules) abstracted on to separate sheets of
paper that are readily available to the clinicians
and nurses; also, diaries for reminding clinic
staff of ensuing examinations should be kept.
These are what can be termed as reminder
systems. Despite these, deficiencies can occur ;
   it is therefore necessary to have systems for
detecting deficiencies and rectifying them before
it is too late.1. Intensity of exam.-clinical, x-ray, sputum etc.
2. Checks on drug-regularity
 3.   Defaulter action
4. Observance of toxic symptoms
5. Criteria for withdrawal from study
regularity, (3) procedures for dealing with
defaulters, and (4) procedures for the recording
Well-designed forms and analysis cards
make analyses easy ; therefore much time
must be spent on them at the design stage.
Also, information collected should be abstrac-
ted periodically on to analysis cards. This
will not only facilitate interim analysis, but also
   highlight deficiencies in the forms, cards and
recording systems, which can then be rectified.
As bias can creep in to laboratory investi-
  gations, it is important to devise systems inof symptoms of toxicity. Finally, and most
important, the circumstances under which a which there is not even scope for bias. For
patient may be withdrawn from the study must instance, when smears are examined, or cultu-
be stated very clearly. For instance, the criteria res or sensitivity tests read, or urine tests under-
could be serious radiographic or clinical dete- taken, it should be arranged that the laboratory
rioration in the presence of a positive sputum of technicians are unaware of the source of indi-
major drug-toxicity. It must be emphasised that vidual specimens.
all these procedures must be implemented alike Finally, it is essential to have quality con-
for all patients, regardless of the treatment trol for laboratory tests and for drugs that are
regimen. in use in the study. At the Tuberculosis Chemo-therapy Centre, we keep track of the standards
Conduct of the study in the laboratory investigations by slipping
All that has been said so far relates to the.   in controls without prior warning and by perio-
planning of a controlled clinical trial. When dic reviews of the incidence of contamination
the plan is fully evolved, a protocol should be and smear-positive culture-negative results. As
written up which contains all these points, and regards drugs, assays are undertaken routinely
made available to all participating physicians. on arrival, and if necessary at periodic intervals
The protocol should be treated as a sacrosanct thereafter.
document, and scrupulously observed in every Evaluation of results
9. Conduct of the study Even in the case of well-planned and well-
1. Strict adherance to protocol
Reminder systems
Deficiency-detecting systems
2. Design of forms and analysis cards
3 Periodic abstraction of information
4. Avoidance of bias in lab. investigations
5. Quality control-lab. tests, drugs
10. Evaluation of results
I. Be wary in excluding patients from analyses
2. Check for similarity between series in
(a) initial condition
(b) intensity of examination during treatment
3. Objective methods to ensure bias-free comparison
(a) Independent assessor for x-ray reading
(b) Clear definitions of fav. and unfav. response
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conducted studies, great care has to be taken in
the evaluation of the results. One common
error is the exclusion of patients from final
analyses. Sometimes, the reasons are obviously
unrelated to the treatment regimen; in such
cases, it is sufficient to establish that the exclu-
sions have occurred to a similar extent in both
series. However, we have had examples at
previous conferences where deaths from tuber-
culosis were conveniently excluded and cheer-
fully optimistic conclusions drawn from the
findings in the survivors. Such procedures must
be deplored strongly. The rule should be to
describe the progress of all patients admitted
to the study who belong to the population
defined earlier (Slide 2).
Although random allocation can be expec-
ted to yield 2 series which are very similar in
their initial condition, nevertheless, analyses
should be undertaken to check that the 2
series were in fact similar on admission. Also,
analyses should be undertaken to check
that the actual intensity of examination during
treatment was the same.
Finally, for assessing x-ray progress, it is
important to obtain the services of an indepen-
dent assessor who is not connected with the
day-to-day management of the patients. Fur-
ther, the x-rays should be fed to the assessor
in strict sequence of the patient serial number,
which is by design a random sequence. Defini-
tions of favourable and unfavourable response
must be clear-cut, and applied alike to all the
patients regardless of the treatment regimen. In
other words, classifying patients as having a
favourable or unfavourable response on an
individual basis without laying down strict
definitions is a highly objectionable procedure.
No evaluation can be complete without
tests of statistical significance. However, the
results of these tests must not be regarded as
giving proof of existence or proof of non-exis-
tence of a difference. Thus, when we say that
a difference is statistically significant, all that
we mean is that the likelihood of it being a
fluke observation less than 5%.
I would like to stress that planning, conduct
and evaluation are not three water-tight com-
partments that can be dealt with independently
by different people or different committees.
Atleast one individual, preferably the chief
investigator, must be deeply involved in all
three stages, and all the other participants must
understand and appreciate the rudiments of
controlled experimentation, if the outcome of
such efforts is to be valuable.
